Schechter Investment Advisors LLC Sells 11,403 Shares of Novo Nordisk A/S (NYSE:NVO)

Schechter Investment Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 34.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,440 shares of the company's stock after selling 11,403 shares during the period. Schechter Investment Advisors LLC's holdings in Novo Nordisk A/S were worth $1,489,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL grew its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the period. Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $33,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 2.9%

Shares of NVO opened at $68.93 on Monday. The stock has a market capitalization of $307.77 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $143.49. The stock has a fifty day moving average of $70.35 and a 200-day moving average of $74.91.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.